Lantus is a long-acting insulin that was first approved by the FDA in 2000. It is typically used to treat type 2 diabetes and is taken once daily. Lantus is manufactured by Sanofi-Aventis and its generic name is insulin glargine.
Toujeo is a long-acting insulin that was approved by the FDA in 2015. It is a newer insulin that is very similar to Lantus, another long-acting insulin. Toujeo is a once-daily insulin that is given by injection. It is designed to provide a steady level of insulin throughout the day and night.
Lantus is the winner because it has a more consistent effect and lasts longer.